Er Chen

Director, Global Value & Access Lead Roctavian
BioMarin Pharmaceuticals Inc.
Novato, California, United States

Presentation(s):

• OC 20.2 - Gene Therapy in Hemophilia A: the Impact of Valoctocogene Roxaparvovec on Patient Outcomes – Initial Results from Patient Reported Outcomes, Burdens and Experiences (PROBE) from the GENEr8-1 Trial

  Sunday, June 25, 2023
  15:00 – 15:15 ET